Trial · NCT03805750

Trial of Cannabis for Essential Tremor

NCT03805750, Phase 1, Phase 2, Completed, University of California, San Diego; results first posted 2022-10-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of Cannabis for Essential Tremor. Trials, record NCT03805750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03805750

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of Cannabis for Essential Tremor
NCT number: NCT03805750
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 7 participants, actual
Lead sponsor: University of California, San Diego
Conditions: Essential Tremor
Interventions: CBD/THC, Placebo oral capsule
First posted: 2019-01-16
Last updated: 2022-10-13
Results first posted: 2022-10-13

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Digital Spirography	Day 22 (100 minutes post-dose)	The tremor mean amplitude calculated using computerized spirography to measure kinetic tremors.
Secondary	Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS)	Baseline and Day 22	The performance sub scale of the TETRAS will be used to measure tremor severity. The scale ranges from 0 to 60 points (0 being no tremor).
Secondary	Global Impression of Change	Day 22	The Global impression of change will be calculated based on both physician and patient report. The scale ranges from a score of 1 (very much improved) to 7 (very much worse) with a score of 4 indicating 'no change'.
Secondary	Number of Participants Reporting Adverse Events Based on Common Terminology Criteria	Days 1, 3, 6, 22	Side effects survey
Secondary	Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS)	Day 22	This is a scale looking at risk assessment of suicidality. The presence of any positive responses will lead to further evaluation.
Secondary	Number of Participants With New Study-related Electrocardiogram (EKG) Abnormalities	Day 22	Electrocardiographic changes from baseline measures will trigger further evaluation. EKG's will be rated as normal/abnormal relative to the baseline EKG reading, and abnormal findings will be rated as clinically significant/not clinically significant.
Secondary	Accelerometry-based Assessment of Tremor Severity	Baseline and Day 22	The spectral power density measure of accelerometry data to measure will serve as a measure of tremor severity, comparing tremor amplitude from this digital biomarker at the time of the primary outcome to the same measure at baseline.

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Digital Spirography	Day 22 (100 minutes post-dose)		millimeters of tremor amplitude	MEAN
SECONDARY	Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS)	Baseline and Day 22		score on a scale	MEAN
SECONDARY	Global Impression of Change	Day 22		score on a scale	MEAN
SECONDARY	Number of Participants Reporting Adverse Events Based on Common Terminology Criteria	Days 1, 3, 6, 22		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS)	Day 22		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With New Study-related Electrocardiogram (EKG) Abnormalities	Day 22		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Accelerometry-based Assessment of Tremor Severity	Baseline and Day 22	Participants in both treatment arms will undergone tremor measurement using accelerometry as a surrogate of tremor severity.	Proportion of baseline spectral power	MEAN

Source ClinicalTrials.gov

Results by group74

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Digital Spirography	CBD/THC		1.04	Standard Deviation 0.57	millimeters of tremor amplitude
Digital Spirography	Placebo		1.00	Standard Deviation 0.42	millimeters of tremor amplitude
Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS)	CBD/THC		-8.07	Standard Deviation 5.71	score on a scale
Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS)	Placebo		-10.3	Standard Deviation 3.9	score on a scale
Global Impression of Change	CBD/THC	Clinical Global Impression of Change	3	Full Range 3 to 4	score on a scale
Global Impression of Change	Placebo	Clinical Global Impression of Change	4	Full Range 2 to 4	score on a scale
Global Impression of Change	CBD/THC	Patient Global Impression of Change	3	Full Range 3 to 4	score on a scale
Global Impression of Change	Placebo	Patient Global Impression of Change	4	Full Range 2.5 to 4	score on a scale
Number of Participants Reporting Adverse Events Based on Common Terminology Criteria	CBD/THC	Ringing in ears	7		Participants
Number of Participants Reporting Adverse Events Based on Common Terminology Criteria	Placebo	Ringing in ears	6		Participants

1 to 10 of 74Source ClinicalTrials.gov

See all 74 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention - 4 Weeks	STARTED	CBD/THC First Then Placebo	3
First Intervention - 4 Weeks	STARTED	Placebo First Then CBD/THC	4
First Intervention - 4 Weeks	COMPLETED	CBD/THC First Then Placebo	3
First Intervention - 4 Weeks	COMPLETED	Placebo First Then CBD/THC	4
First Intervention - 4 Weeks	NOT COMPLETED	CBD/THC First Then Placebo	0
First Intervention - 4 Weeks	NOT COMPLETED	Placebo First Then CBD/THC	0
Second Intervention - 4 Weeks	STARTED	CBD/THC First Then Placebo	3
Second Intervention - 4 Weeks	STARTED	Placebo First Then CBD/THC	4
Second Intervention - 4 Weeks	COMPLETED	CBD/THC First Then Placebo	3
Second Intervention - 4 Weeks	COMPLETED	Placebo First Then CBD/THC	2

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events60

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Ringing in ears	Ear and labyrinth disorders	CBD/THC	7	7
other	Ringing in ears	Ear and labyrinth disorders	Placebo	6	7
other	Numbness/tingling	Nervous system disorders	CBD/THC	4	7
other	Numbness/tingling	Nervous system disorders	Placebo	4	7
other	Dyspnea on exertion	Respiratory, thoracic and mediastinal disorders	CBD/THC	4	7
other	Dyspnea on exertion	Respiratory, thoracic and mediastinal disorders	Placebo	4	7
other	Watery eyes	Eye disorders	CBD/THC	3	7
other	Watery eyes	Eye disorders	Placebo	3	7
other	Runny nose	Respiratory, thoracic and mediastinal disorders	CBD/THC	3	7
other	Runny nose	Respiratory, thoracic and mediastinal disorders	Placebo	2	7

1 to 10 of 60Source ClinicalTrials.gov

See all 60 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	CBD/THC	0	7
Total, all-cause mortality	Placebo	0	7
Total, other adverse events	CBD/THC	7	7
Total, other adverse events	Placebo	6	7
Total, serious adverse events	CBD/THC	0	7
Total, serious adverse events	Placebo	0	7

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
CBD/THC vs Placebo: Number of Participants With New Study-related Electrocardiogram (EKG) Abnormalities	Trial comparisons
CBD/THC vs Placebo: Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS)	Trial comparisons
CBD/THC vs Placebo: deaths from any cause	Trial comparisons
CBD/THC vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03805750

GET https://conductscience.org/api/trials/v1/NCT03805750/results?page=2

API reference For AI assistants